The North America diagnostic radiopharmaceutical market is expected to remain a major contributor to the global industry through 2034, supported by the region’s advanced healthcare infrastructure, increasing adoption of molecular imaging, and growing demand for precise disease diagnosis. Diagnostic radiopharmaceuticals are increasingly used in positron emission tomography (PET) and...